Abstract
Purpose: This study aimed to determine the therapeutic effect of Bushen Jiangu Decoction (BJD) on osteoporosis (OS) in rats.Methods: The animals were divided into the following groups: control group, rats received no treatment; ovariectomy (OVX) group, rats subjected to OVX surgery and were treated with normal saline; OVX + Fosamax group, rats that received OVX and were treated with 2 mg/kg/week of Fosamax; low-dose BJD (40 mg/kg/day), medium-dose BJD (80 mg/kg/day) and high-dose BJD (160 mg/kg/day) groups, where rats received OVX surgery with BJD doses of 40, 80 and 160 mg/kg/day, respectively. At four weeks after treatment with OVX, Fosamax or BJD was orally administered for four months. Bone mineral density (BMD) was assessed, while serum hormone, serum levels of follicle-stimulating hormone (FSH), alkaline phosphatase (ALP), estradiol (E2), luteinizing hormone (LH), osteocalcin (OC) and telopeptides of collagen type I (CTx) were measured by enzyme linked immunosorbent assay (ELISA).Results: The results demonstrated that the reduced BMDs of L4 femurs and vertebrae were inhibited by BJD. Furthermore, BJD significantly elevated the serum levels of FSH, E2 and LH in OS rats. Furthermore, the serum CTx, ALP and OC levels of these rats dramatically decreased, when compared to the OVX group.Conclusion: These findings suggest that BJD can improve OVX-induced OS.Keywords: Bushen Jiangu decoction, Osteoporosis, Bone mineral density, Serum biochemistry
Highlights
The postmenopausal osteoporosis (OS), which is mainly characterized by degraded bone microstructure and reduced bone density, is considered as a systemic bone disease that mainly affects postmenopausal women [1,2]
Bushen Jiangu Decoction (BJD) treatment dramatically increased Bone mineral density (BMD), and this was decreased by OVX (p < 0.05)
These results suggested that BJD could enhance the reduced BMD in OS rats
Summary
The postmenopausal osteoporosis (OS), which is mainly characterized by degraded bone microstructure and reduced bone density, is considered as a systemic bone disease that mainly affects postmenopausal women [1,2]. The World Health Organization have reported that OS affects millions of people in the United States, Europe and Japan, and the incidence of OS dramatically increases along with age, which is dramatically higher in women over 50 years old [3,4]. This may bring huge physician and economic burden to patients and society [5-7]. It was reported that hormone replacement therapy (HRT) has high exhibited efficacy and safety in the treatment of postmenopausal OS [8,9]. HRT has side effects in long-term treatment, such as injury to reproductive tissues [10-12]. Since traditional medicines for the treatment of OS have many disadvantages, such as side effects of gastrointestinal reactions and osteonecrosis of the jaw [13,14], more new treatment methods are needed
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call